To compare KRAS mutants in a cancer relevant system, four cell lines: (SW48, SW48 KRASG12D/+, SW48 KRASG12V/+, and SW48 KRASG13D/+) were injected into athymic mice and 14 days of treatment (10 mg kg−1 249C or vehicle control, i.p.; n = 5 for all arms) was started when the average tumor volume reached approximately 100–200 mm3 following random segregation into groups. The gene discussed is KRAS; the disease is cancer.